(Rac)-Besifloxacin hydrochloride 

(Rac)-Besifloxacin Hydrochloride is a fourth generation fluoroquinolone antibiotic. (Rac)-Besifloxacin Hydrochloride is a DNA gyrase and topoisomerase IV inhibitor. (Rac)-Besifloxacin Hydrochloride has broad-spectrum antibacterial activity, it is effective against Gram-negative and Gram-positive aerobic and anaerobic strains and reduces the incidence of drug resistance. (Rac)-Besifloxacin Hydrochloride has anti-inflammatory activity. Besifloxacin Hydrochloride can be used in bacterial conjunctivitis research^[1][2][3][4].

430.30

C₁₉H₂₂Cl₂FN₃O₃

1398566-43-2

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CC(N)CCCC4)=C3Cl)C1=O)O.[H]Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhang JZ, et al. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother. 2008 Jan;61(1):111-6.  [Content Brief]

  [2]. Sanfilippo CM, et al. Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin. Chemotherapy. 2011;57(5):363-71.  [Content Brief]

  [3]. Haas W, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009 Aug;53(8):3552-60.  [Content Brief]

  [4]. Sanders ME, et al. Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis. J Ocul Pharmacol Ther. 2010 Apr;26(2):193-8.  [Content Brief]